Roxana Reyes

Medical Oncology - Thoracic malignacies @oncorosell

[Uğur Özkerim @UOzkerim]

WCLC 2026 is getting closer! 🇰🇷🫁

Eight studies from the Presidential Symposia that I’ll be watching closely in Seoul.

Which one are you most excited about?

#WCLC2026 @IASLC
@OncoAlert @GlopesMd @weoncologists @MedwatchKate @StephenVLiu @ManuelDomine @MedwatchKate @RManochakian

[Kai @bmassutis]

First randomized trial testing circadian rhythm and time of immunotherapy administration show impressive results and some biological correlates open a research field in this setting #ASCO25 ⁦@OncoAlert⁩

[Noemi Reguart @NReguart]

🔊 🚨🚨 Watch out!! Multidisciplinary Tumor Board (MTB) adherence in stage III NSCLC patients predicts outcomes!! One third of stage III pts unable to follow MTB recommendations!!! — a critical gap! Key insights from Markus Joerger #ESMOAmbassadors #ELCC25 @myESMO

[Noemi Reguart @NReguart]

Patterns of disease progression with durvalumab after concurrent cCRT in LE-SCLC in ADRIATIC: time to CNS PD prolonged and lower rates of CNS mets with durvalumab irrespective of PCI use. Nicely presented Dr. Suresh Senan #ESMOAmbassadors #ELCC25 @myESMO

[Instituto Oncológico Dr Rosell @oncorosell]

¿Qué es la #inmunoterapia y por qué está cobrando cada vez más fuerza en la lucha contra el cáncer?

👩‍⚕️ La Dra. Roxana Reyes, oncóloga médica de la Unidad de Tumores Torácicos de #IOR, nos cuenta cómo funciona este tratamiento, en qué casos se administra, y mucho más.

HILO ⬇️🧵

[Roxana Reyes @Rm_Reyesc]

👩🏻‍⚕️FLAURA2 2nd interim OS analysis: HR 0.75(95% CI 0.57-0.97; p=0.0280) for Osimerinib + CT vs Osimertinib monotherapy. How to select the patients who will benefit with the combination? #ELCC24

[Noemi Reguart @NReguart]

Amivantamab and chemotherapy in PAPILLON hits, and stablish a NEW SoC in patients with EGFRm exon 20 insertions, 60% reduccion in the risk of progressio. (PFS 11.4 vs 6.7 mo, HR 0.395, p<0.0001). Interym analisis inmature but preliminary OS HR 0.675. #ESMO2023

[Roxana Reyes @Rm_Reyesc]

Happy to be here with @NReguart despite the weather ☔️ and the incidents on the train trip from Barcelona 🚆 #ESMO2023

[Tactics @tactics_md]

📢 Última llamada

Meet the Professor In Thoracic Tumors ▶️ 28/09

Las reputadas Dras. @NReguart y @EnriquetaFelip coordinan este encuentro virtual con referentes nacionales e internacionales de la #Oncología

#MásQueCongresos💙 #MPITT2023

Inscríbete 📲 https://t.co/tOgZEKBu0G

[Roxana Reyes @Rm_Reyesc]

Thrilled to have been at #WCLC23 🫁🔬 Delving into the latest data on lung cancer research - these discoveries are paving the way for a brighter future. 🌟👩‍🔬 Stay tuned for insights that could change lives! 💪💙 @NReguart

[Laura Mezquita @LauraMezquitaMD]

📢 Oferta📍Buscamos Clinical Fellow – Oncólog@ Médic@, Grupo Tumores torácicos @hospitalclinic Barcelona

Te esperamos 😉 en nuestro equipo 🫁 @Rm_Reyesc @vmalbarran @jc_laguna_ @nvinolas
liderado por @NReguart

🩺🧬👩🏻‍⚕️👨🏼‍🔬

+ info 👇 https://t.co/HRtqCJ4PxV

Please RT! 🙏

[Hospital Clínic @hospitalclinic]

Per aquest motiu des de @gencatdigital, @ciberseguracat i @mossos es continuarà fent sensibilització per evitar que els pacients siguin víctimes de fraus que es poden derivar de la fuita de dades.

⚠️ Si reps un sms demanant credencials o amb enllaços, no prové del #CLÍNIC ⚠️

[Víctor Albarrán-Artahona @vmalbarran]

👑 Best poster in Epidemiology and Tobacco control in #lNSCLC 🫁🏆

Data from the SCAN study: Role of occupation in pts with NSCLC pts from Barcelona in Spain 🇪🇸

Proud of representing @jc_laguna_ at #ELCC23

Assessment of risk factors is a priority!

[Roxana Reyes @Rm_Reyesc]

Real life journey 🚀 to decide the best treatment option for our patients @DrSanjayPopat @myESMO #ELCC23

[Víctor Albarrán-Artahona @vmalbarran]

#ELCC23

🙇🏻‍♂️ Masterclass with Dr. Mezquita on Radon gas + other neglected risk factors in lung carcinogenesis 🫁

‼️ Indoor radon exposure associated with up to 15% of lung cancer cases ☢️

👷🏻‍♀️👷🏽‍♂️ Occupational exposures and genetic predisposition matters! 🧬

@LauraMezquitaMD

[Roxana Reyes @Rm_Reyesc]

Great discussion about multidisciplinary management of distinct oligometastic scenarios in EGFR-driven NSCLC at #ELCC23 @NReguart @myESMO

[Maria Vidal @MVidalMD]

Os recibirán nuestro equipo de residentes para explicaros esto y muucho más!! #residentsCLINIC#oncoclinic#MIR2023 @hospitalclinic @prat_aleix @MuozMateu @badamo20

[Teresa Gorría @Teresa_Gorria]

¿Quieres realizar la residencia de Oncología Médica en el Hospital Clínic de Barcelona?🧬🤩

📍Ven a vernos el próximo 29.03.23 (10h) en el Paranimf de la Facultat de Medicina

Con ganas de conoceros 🍀!!

#CLINICResidentFestival #OncoClinic @hospitalclinic
➕info👇🏼

[Marcelo Sanchez @Marcelo97843311]

Dra Noemí Reguart @NReguart del @hospitalclinic revisando el papel de la inmunoterapia en el tratamiento de los estadios precoces del cáncer de pulmón @roche_es